Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Pulmonx Corporation
During the third quarter, device company fundraising totaled $3.3bn; while in vitro diagnostic firms and research tools players raised $3.4bn.
Public Company Edition: Outside the US, Zai Lab raised more in its recent Hong Kong initial public offering – $766.4m – than PMV, Prelude, Taysha, Graybug and Greenwich combined. Also, Gilead priced debt to fund its $21bn Immunomedics buy and ADC Therapeutics raised $204m.
The company originally filed to list on the NASDAQ in February but withdrew as the pandemic hit.
Pulmonx announced US FDA approval of its Zephyr endobronchial valve system for treating severe emphysema patients. This makes it the first minimally invasive device to be approved in the US for treating severe emphysema, a severe form of chronic obstructive pulmonary disease.
- Diagnostic Equipment & Supplies
- Implantable Devices
Diagnostic Imaging Equipment & Supplies
- Digital Imaging